Skip to content

To study the effect of Pomegranate Effervescent Granules in the treatment of Acidity

Evaluation of the efficacy of Pomegranate Effervescent Granules in the management of Acid Peptic disorders: An open label multi-centric prospective clinical study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/07/008999
Enrollment
150
Registered
2017-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of either sex, aged between 18-60 years, suffering from cardinal signs and symptoms of acid peptic disorders

Interventions

Intervention1: Pomegranate effervescent granules: Effervescent granules prepared from fruit peel of Punica Granatum. They are to be administered orally in a dose of 2.5g (1 sachet) twice a day dissolv

Sponsors

Dr Pratima Tatke
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from minimum 5 of the cardinal signs and symptoms of acid peptic disorders- a)sour or pungent eructations/belching b)retrosternal /throat burning c)epigastric burning/pain d)Nausea e)regurgitation/ vomiting f)unsatisfactory digestion g)loss of appetite h)heaviness in body i)tiredness in absence of physical activity 2. Patients on prolonged treatment with NSAIDs 3) Patients willing to comply with study procedures and requirements

Exclusion criteria

Exclusion criteria: Patients suffering from following conditions, if any- 1.Hemoglobin 2.Known history of carcinogenic pathology, severe per rectal bleed etc. 3.Known history of coagulopathies. 4.Liver function criteria found to be 2.5 times the upper normal limits. 5.Known history of severe cardiac, pulmonary, hepatic or renal diseases like Coronary Artery Disease, Cardiomyopathy, Pleural effusion, Pneumonia, Hepatitis, Liver Cirrhosis, Nephropathy, Nephritis, etc. 6.Pregnant or Lactating women. 7.Patients who participated in any clinical trial within 30 days before enrolment into the study

Design outcomes

Primary

MeasureTime frame
1. Improvement in the clinical signs and symtoms 2. Improvement in GSRS ScoreTimepoint: On day 15 and day 29 both outcomes will be assessed

Secondary

MeasureTime frame
Changes with improvement in gastric mucosa in patients with peptic ulcer.Timepoint: Day 29- Gastroendoscopy will be repeated post the study for patients with ulcer for comparison

Countries

India

Contacts

Public ContactDr Supriya Bhalerao

Interactive Research School for Health Affairs

supriya.bhalerao@gmail.com02024366920

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 13, 2026